Stifel analyst Alex Schwartz raised his price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $15.00 (from $12.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Momenta Phama (MNTA) Announces Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281January 5, 2018 8:06 AM Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy VolunteersJanuary 5, 2018 8:00 AM Momenta Phama (MNTA), Mylan N.V. (MYL) Announce Development Strategy for M710January 3, 2018 4:08 PM Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)January 3, 2018 4:05 PM